June 10, 2021
Abdi ibrahim acquıres 90 percent of inoliva
Abdi İbrahim strengthened its international credentials by acquiring a 28,5 percent share in the Swiss biotechnology company OM Pharma in September last year. It has now announced the acquisition of a 90 percent share in INOLIVA, a consumer health company operating in Turkey. Nezih Barut, Chairman of the Board of Directors of Abdi İbrahim, who oversaw the incorporation of INOLIVA, which was established in 2019 and stood out in the market with its innovative products in a short time, said: ‘Consumer health is developing rapidly all over the world. As Abdi İbrahim, we are competing with the strong brands that we have created in this field. We want to carry the success and leadership we have achieved in prescription drugs to consumer health. We utilize all organic and inorganic growth opportunities. This acquisition, which shows our interest in the field of consumer health, is proof of Abdi İbrahim's investment-oriented growth determination that has been ongoing for 109 years.’’
Abdi İbrahim has been the market leader of the Turkish pharmaceutical sector for the last 19 years and has strengthened its international position through domestic and international investments. The company has raised its status in the consumer health field with the significant acquisition of a 90 percent stake in INOLIVA, founded in 2019 by Eroğlu Holding and Pharmacist Şevket Kaya, adding a new investment to the consumer health industry, as one of the company’s five growth areas.
Established in February 2019, INOLIVA witnessed rapid progress in a short time with its brand Lipozone, a locomotive brand maximizing bioavailability and efficiency in the consumer health market, as well as Çinkoplast and Hepoliva. The acquisition gives Abdi İbrahim a 90 percent stake in the company's partnership structure, while Pharmacist Şevket Kaya maintains a 10 percent share. Operating in the consumer health industry, defined as a priority area in Abdi İbrahim’s VISION 2025 growth strategy, INOLIVA will have the full support of Abdi İbrahim, Turkey's uninterrupted 19-year market leader in the pharmaceutical sector.
Nezih Barut: ‘’Regardless of the conditions, we invest in the future of the sector.”Emphasizing that behind Abdi İbrahim's 109 years of success are the continuous investments that have been made, Abdi İbrahim, Chairman of the Board of Directors Nezih Barut, said: “We have been investing for 109 years with confidence in the future of our country and our sector, regardless of the circumstances. We are proud to lead the industry in terms of our efforts in production, employment, exports and R&D.” Explaining that they are following all organic and inorganic growth opportunities in their target fields, both at home and abroad, Nezih Barut continued: "Last year, we made a significant contribution to demonstrate to the world our commitment to biotechnology during the most challenging times of the pandemic, becoming the first Turkish pharma company to become a strategic partner of a Western pharmaceutical company through the acquisition of a 28.5% share in the Swiss OE Pharma. A year later, we have acquired INOLIVA, demonstrating our desire to grow in consumer health. The company has made a significant impact in the market in a short time with its strategy and product range. This investment will support the acceleration of our international consumer health objectives. As with OM Pharma, the INOLIVA investment is more than just a purchase, rather a confirmation of our confidence in the development and growth potential of the Turkish pharmaceutical industry."
“We want to be an international player in consumer health”
Nezih Barut pointed out that Abdi İbrahim has secured a strong image in the consumer health field with the Youplus, Umca, Hametol and Probest brands, and added that the current portfolio, vision and business model of INOLIVA are in line with Abdi İbrahim's vision on sustainability and innovation. Nezih Barut stated that trends of healthy aging and holistic well-being are becoming widespread, leading to the continuing increase in the presence of protective, functional and holistic medical practices in our lives. Barut said: "Consumer health products lead the growth in the healthcare sector. We are a growth-oriented company, and consumer health is one of the five main growth topics in our 2025 vision. We are determined to continue investing in this field." Nezih Barut emphasized that they would be increasing local production by producing INOLIVA products in Abdi İbrahim’s facilities and that they would be speeding up product development efforts and introducing new product ranges in the form of innovative solutions tailored to the needs of consumers, combining Abdi İbrahim's business development expertise with its entrepreneurial spirit. Nezih Barut continued: "We want to carry our leadership in prescription drugs to the health of consumers much further to become an international player in this field. This move reflects our determination and commitment to this path and reinforces our expertise. At Abdi İbrahim, we believe that INOLIVA products will play a vital role in our efforts to grow through the delivery of innovative and strong brands to the European market, where we are currently planning our introductory strategies."
